MaxCyte, Inc. (LON:MXCT - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as GBX 155.50 ($2.09) and last traded at GBX 160 ($2.15), with a volume of 31853 shares changing hands. The stock had previously closed at GBX 161.10 ($2.16).
MaxCyte Price Performance
The company has a market capitalization of £217.81 million, a price-to-earnings ratio of -6.05 and a beta of 1.13. The stock has a fifty day simple moving average of GBX 179.57 and a 200-day simple moving average of GBX 259.80. The company has a debt-to-equity ratio of 8.59, a current ratio of 9.81 and a quick ratio of 14.38.
About MaxCyte
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Recommended Stories
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
